Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Agenus Inc.NASDAQ: AGEN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $33.74M rose 40.2% year over year, ahead of the +24.5% change in trailing-twelve-month revenue. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $130.95M (+14.7%) for the fiscal year ending Dec 2026, a step up from the +10.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $33.74M-1.4% QoQ
- Last fiscal yearDec 2025
- $114.2M+10.4% YoY
- LTMMar 2026
- $123.87M+24.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +40.2% | +32.3% | -7.8 pp |
| 1 year | +10.4% | +14.7% | +4.3 pp |
| 3-year CAGR | +5.2% | +2.5% | -2.8 pp |
| 5-year CAGR | +4.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 114.2M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- -21.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 114.2M | +10.4% |
| FY2024 | 2024-12-31 | 103.46M | -33.8% |
| FY2023 | 2023-12-31 | 156.31M | +59.5% |
| FY2022 | 2022-12-31 | 98.02M | -66.8% |
| FY2021 | 2021-12-31 | 295.67M | — |
Revenue vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 revenue of $123.87M is the highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +24.5% is the highest of 6, against a peer median of -52.6%.
- Over three fiscal years its annual growth of +5.2% compares with a peer median of -44.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $123.87M | +24.5% | +5.2% | |
| LTM Mar 2026 | $15.04M | -0.9% | +3.2% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $11.98M | -12.2% | -29.1% |
| LTM Mar 2026 | $6.32M | -52.6% | -59.0% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | -81.5% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding AGEN) | $0 | -52.6% | -44.0% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Cost of Revenue | 182.08M | 197.26M | 237.68M | 156.01M | 80.36M |
| Gross Profit | 113.59M | (99.24M) | (81.37M) | (52.55M) | 33.84M |
| Gross Margin | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| Research & Development | 178.61M | 0 | 234.57M | 155.53M | 0 |
| Selling, General & Admin | 76.36M | 81.01M | 78.74M | 71.88M | 54.39M |
| Operating Expenses | 87.84M | 80.19M | 78.18M | 67.92M | 54.39M |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBITDA | 43.78M | (161.85M) | (145.92M) | (101.3M) | 62.19M |
| EBITDA Margin | 14.8% | -165.1% | -93.4% | -97.9% | 54.5% |
| Operating Income | 25.75M | (179.43M) | (159.55M) | (120.48M) | (20.56M) |
| Operating Margin | 8.7% | -183.0% | -102.1% | -116.4% | -18.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 65.72M | 61.86M | 97.93M | 117.63M | 55.27M |
| Other Income / Expenses | (54.47M) | (51.23M) | (97.89M) | (111.8M) | 17.47M |
| Income Before Tax | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (3.08M) |
| Pre-Tax Margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.93M) | (220.07M) | (245.76M) | (227.21M) | 115K |
| Net Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (Basic) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| EPS (Diluted) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| Weighted Avg Shares | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Weighted Avg Shares (Diluted) | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.